A European Medicines Agency
review has concluded that the
benefits of combined hormonal
contraceptives still outweigh
the risks, particularly the wellknown
but small risk of venous
thromboembolism (VTE).
However the EMA says it
will mandate updated product
information for oral contraceptives
“to help women make informed
decisions about their choice of
contraception”.
The review also looked at the
risk of arterial thromboembolism
and found it was “very low,” with
patients who have been taking
contraceptives without any
problem told there is no reason to
stop on the basis of the review.
“But it is important that you are
aware of the risk of blood clots
associated with these medicines,
even though it is very low”.
Oral contraceptives differ in
terms of VTE risk depending on
the type of progestogen they
contain, with the lowest found for
those containing levonorgestrel,
norethisterone or norgestimate.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Nov 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Nov 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.